4282 Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review, Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Psychiatric 

and Behavioral Genetics. 

Date: February 12–13, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Cheryl M. Corsaro, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2204, 

MSC 7890, Bethesda, MD 20892, (301) 435–

1045, corsaroc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cancer 

Immunopathology and Immunotherapy 

Study Section: Quorum. 

Date: February 15–16, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Steven B. Scholnick, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6152, 

MSC 7804, Bethesda, MD 20892, 301–435–

1719, scholnis@csr.nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Molecular 

Neuropharmacology and Signaling Study 

Section. 

Date: February 21–22, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Jurys Washington Hotel, 1500 New 

Hampshire Avenue, NW., Washington, DC 

20032. 

Contact Person: Syed Husain, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7850, Bethesda, MD 20892–7850, (301) 

435–1224, husains@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Applied 

Metabolomic Technologies. 

Date: February 21–22, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Geoffrey White, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5148, 

MSC 7849, Bethesda, MD 20892, 301–435–

2417, whitege@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Bioengineering and Imaging. 

Date: February 21–22, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Khalid Masood, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5120, 

MSC 7854, Bethesda, MD 20892, 301–435–

2392, masoodk@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Microbiology Integrated Review Group; 

Prokaryotic Cell and Molecular Biology 

Study Section. 

Date: February 21–22, 2007. 

Time: 8:30 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Mayflower Hotel, 1127 Connecticut 

Avenue, Washington, DC 20036. 

Contact Person: Diane L. Stassi, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892, (301) 435–

2514, stassid@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Nanotechnology in Medicine and Biology—

Synthesis, Theory and Analysis. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Ave, Bethesda, MD 20814. 

Contact Person: Nitsa Rosenzweig, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1102, 

MSC 7760, Bethesda, MD 20892, (301) 435–

1747, rosenzweign@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Neural Basis of Psychopathology, 

Addictions and Sleep Disorders Study 

Section. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites Hotel Washington, 

DC, 1250 22nd Street, NW., Washington, DC 

20037. 

Contact Person: Julius Cinque, MS, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5186, 

MSC 7846, Bethesda, MD 20892, (301) 435–

1252, cinquej@csr.nih.gov. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Social Psychology, Personality and 

Interpersonal Processes Study Section. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Wyndham Hotel, 101 West 

Fayette Street, Baltimore, MD 21201. 

Contact Person: Anna L. Riley, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7759, Bethesda, MD 20892, 301–435–

2889, rileyann@csr.nih.gov. 

Name of Committee: Cardiovascular 

Sciences Integrated Review Group; 

Myocardial Ischemia and Metabolism Study 

Section. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: St. Gregory Hotel, 2033 M Street, 

NW., Washington, DC 20036. 

Contact Person: Joyce C. Gibson, DSC, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4130, 

MSC 7814, Bethesda, MD 20892, 301–435–

4522, gibsonj@csr.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Cellular, 

Molecular and Integrative Reproduction 

Study Section. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Ave, Bethesda, MD 20814. 

Contact Person: Syed M. Amir, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6172, 

MSC 7892, Bethesda, MD 20892, 301–435–

1043, amirs@csr.nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Nuclear Dynamics 

and Transport. 

Date: February 22, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Alessandra M. Bini, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5142, 

MSC 7840, Bethesda, MD 20892, 301–435–

1024, binia@csr.nih.gov. 

Name of Committee: Renal and Urological 

Studies Integrated Review Group; 


ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices 4283 

Pathobiology of Kidney Disease Study 

Section. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Churchill Hotel, 1914 

Connecticut Avenue, NW., Washington, DC 

20009. 

Contact Person: Krystyna E. Rys-Sikora, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4016J, 

MSC 7814, Bethesda, MD 20892, 301–451–

1325, ryssokok@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Viral 

Detection and Diagnostics. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Soheyla Saadi, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3211, 

MSC 7808, Bethesda, MD 20892, 301–435–

0903, saadisoh@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Medical Imaging and Exploratory 

Ultrasound. 

Date: February 22–23, 2007. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bahia Resort Hotel, 998 West 

Mission Bay Drive, San Diego, CA 92109. 

Contact Person: Leonid V. Tsap, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5128, 

MSC 7854, Bethesda, MD 20892, 301–435–

2507, tsapl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Retinopathy 

Studies. 

Date: February 22, 2007. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Mayflower Hotel, 1127 

Connecticut Avenue, NW., Washington, DC 

20036. 

Contact Person: Raya Mandler, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217, 

MSC 7840, Bethesda, MD 20892, 301–402–

8228, rayam@csr.nih.gov. 

Name of Committee: Health of the 

Population Integrated Review Group; 

Behavioral Genetics and Epidemiology Study 

Section. 

Date: February 22–23, 2007. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sir Francis Drake Hotel, 450 Powell 

Street, San Francisco, CA 94102. 

Contact Person: Elisabeth Koss, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3152, 

MSC 7770, Bethesda, MD 20892, 301–435–

0906, kosse@csr.nih.gov. 

Name of Committee: Health of the 

Population Integrated Review Group; 

Neurological, Aging and Musculoskeletal 

Epidemiology Study Section. 

Date: February 22–23, 2007. 

Time: 8:30 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: Pier 5 Hotel, 711 Eastern Avenue, 

Baltimore, MD 21202. 

Contact Person: Heidi B. Friedman, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1012A, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1721, hfriedman@csr.nih.gov. 

Name of Committee: Hematology 

Integrated Review Group; Hemostasis and 

Thrombosis Study Section. 

Date: February 22, 2007. 

Time: 8:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Chevy Chase, 5520 

Wisconsin Avenue, Chevy Chase, MD 20815. 

Contact Person: Chhanda L. Ganguly, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1739, gangulyc@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Microbiology Integrated Review Group; 

Host Interactions with Bacterial Pathogens 

Study Section. 

Date: February 22, 2007. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Palomar Hotel, 2121 P Street, 

Washington, DC 20037. 

Contact Person: Marian Wachtel, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3208, 

MSC 7858, Bethesda, MD 20892, (301) 435–

1148, wachtelm@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Microbiology Integrated Review Group; 

Virology—A Study Section. 

Date: February 22–23, 2007. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: George Washington University Inn, 

824 New Hampshire Ave., NW., Washington, 

DC 20037. 

Contact Person: Joanna M. Pyper, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3198, 

MSC 7808, Bethesda, MD 20892, (301) 435–

1151, pyperj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; MEDI/BMIT 

Conflict Meeting. 

Date: February 22, 2007. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Weihua Luo, MD, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5114, 

MSC 7854, Bethesda, MD 20892, 301–435–

1170, louw@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Genetics 

and Psychopathology. 

Date: February 22, 2007. 

Time: 2 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sir Francis Drake Hotel, 450 Powell 

Street, San Francisco, CA 94102. 

Contact Person: Elisabeth Koss, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3152, 

MSC 7770, Bethesda, MD 20892, 301–435–

0906, kosse@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group, Microscopic Imaging Study Section. 

Date: February 23, 2007. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Courtyard, San Francisco 

Downtown, 299 Second Street, San 

Francisco, CA 94105. 

Contact Person: Ross D. Shonat, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1115, 

MSC 7849, Bethesda, MD 20892, 301–435–

2786, shonatr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Nanotechnology for Heart, Lung Blood 

Disorders. 

Date: February 23, 2007. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave., NW., Washington, DC 20037. 

Contact Person: Alexandra M. Ainsztein, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5144, 

MSC 7840, Bethesda, MD 20892, 301–451–

3848, ainsztea@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Clinical 

Hematology. 

Date: February 23, 2007. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Chevy Chase, 5520 

Wisconsin Avenue, Chevy Chase, MD 20815. 

Contact Person: Chhanda L. Ganguly, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118, 

MSC 7802, Bethesda, MD 20892, (301) 435–

1739, gangulyc@csr.nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.306, 

Comparative Medicine; 93.333, Clinical 

Research, 93.306, 93.333, 93.337, 


ycherry on PROD1PC64 with NOTICES
4284 Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices 

93.393–93.396, 93.837–93.844, 93.846–

93.878, 93.892, 93.893, National 

Institutes of Health, HHS). 

Dated: January 18, 2007. 

David Clary, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–368 Filed 1–29–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Inhaled Nitrite Therapy 

for the Treatment of Pulmonary 

Conditions 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

contemplating the grant of an exclusive 

license to practice the invention 

embodied in: PCT patent applications 

PCT/US2004/21985 and PCT/US2004/ 

22232, filed July 9, 2004, both entitled 

‘‘Use of Nitrite Salts for the Treatment 

of Cardiovascular Conditions’’ [HHS 

Reference Number: E–254–2003/2–3–

PCT–01], to Aires Pharmaceuticals, Inc., 

a portfolio company of ProQuest 

Investments LLC, Princeton, N.J. The 

field of use of inhaled administration of 

nitrite salts for this exclusive license 

may be limited to the use of inhaled 

formulations of nitrite salts for the 

treatment of Pulmonary Hypertension 

and pulmonary and/or cardiopulmonary 

conditions. The United States of 

America is an assignee of the patent 

rights in these inventions. 

DATES: Only written comments and/or 

application for a license, which are 

received by the NIH Office of 

Technology Transfer on or before April 

2, 2007 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Susan Carson, D.Phil., Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

E-mail: carsonsu@od.nih.gov; 

Telephone: (301) 435–5020; Facsimile: 

(301) 402–0220. 

SUPPLEMENTARY INFORMATION: The core 

invention is the unexpected finding that 

low, physiological and non-toxic 

concentrations of sodium nitrite are able 

to increase blood flow and produce 

vasodilation by infused and nebulized 

routes of administration. Pulmonary 

Hypertension (PH) occurs as a primary 

or idiopathic disease as well as 

secondary to a number of pulmonary 

and systemic diseases, such as neonatal 

PH and sickle cell disease. There is no 

cure for pulmonary hypertension, a 

nitric-oxide deficient state characterized 

by pulmonary vasoconstriction and 

systemic hypoxemia and therapies vary 

in efficacy and cost. Recent studies by 

NIH researchers and their collaborators 

provided evidence that the blood anion 

nitrite contributes to hypoxic 

vasodilation through a heme-based, 

nitric oxide (NO)-generating reaction 

with deoxyhemoglobin and potentially 

other heme proteins [Nature Medicine 

2003 9: 1498–1505]. These initial results 

indicate that sodium nitrite can be used 

as a potential cost-effective platform 

therapy for a wide variety of disease 

indications characterized broadly by 

constricted blood flow or hypoxia. 

These results have been further 

corroborated by work in the neonatal 

lamb model for PH. Inhaled sodium 

nitrite delivered by aerosol to newborn 

lambs with hypoxic pulmonary 

hypertension elicited a rapid and 

sustained reduction (65%) in hypoxiainduced pulmonary hypertension. 

Pulmonary vasodilation elicited by 

aerosolized nitrite was 

deoxyhemoglobin- and pH-dependent 

and was associated with increased 

blood levels of iron-nitrosylhemoglobin. Notably, short term 

delivery of nitrite dissolved in saline 

through nebulization produced 

selective, sustained pulmonary 

vasodilation with no clinically 

significant increase in blood 

methemoglobin levels. [Nature 

Medicine 2004 10: 1122–1127]. Method 

of use claims for nitrite salt 

formulations are directed to conditions 

associated with high blood pressure, 

decreased blood flow and for the 

treatment of specific conditions such as 

pulmonary hypertension and other 

indications. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: January 22, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–1378 Filed 1–29–07; 8:45 am] 

BILLING CODE 4140–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Co-Exclusive 

License: Prevention and Treatment of 

Human Cancer and Tumors by 

Inhibitors of Any or All of the 

Adenosine Receptor Subtypes 

Covered by the Licensed Patent Rights 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of a coexclusive license to practice the 

invention embodied in Patent 

Applications U.S. 60/340,772, filed on 

12/12/2001, U.S. 60/342,582, filed on 

12/19/2001, PCT/US2002/036829, filed 

on 11/14/2002, and corresponding EP, 

CA, AU, and JP filings, as well as U.S. 

10/498,416, filed on 06/10/2004; 

entitled ‘‘Methods for using 

extracellular adenosine inhibitors and 

adenosine receptor inhibitors to 

enhance immune response and 

inflammation’’, all by Michail V. 

Sitkovsky, and Akio Ohta, to Redox 

Therapies, Inc., having a place of 

business in Boston, MA. The patent 

rights in this invention have been 

assigned to the United States of 

America. 

DATES: Only written comments and/or 

application for a license that are 

received by the NIH Office of 

Technology Transfer on or before April 

2, 2007 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Cristina Thalhammer-Reyero, Ph.D., 

M.B.A., Office of Technology Transfer, 


ycherry on PROD1PC64 with NOTICES